<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR42">
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Galanis</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Markovic</surname>
    <given-names>SN</given-names>
   </name>
   <name>
    <surname>Suman</surname>
    <given-names>VJ</given-names>
   </name>
   <name>
    <surname>Nuovo</surname>
    <given-names>GJ</given-names>
   </name>
   <name>
    <surname>Vile</surname>
    <given-names>RG</given-names>
   </name>
   <name>
    <surname>Kottke</surname>
    <given-names>TJ</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase II trial of intravenous administration of reolysinÂ® (reovirus serotype-3-dearing strain) in patients with metastatic melanoma</article-title>
  <source>Mol Ther</source>
  <year>2012</year>
  <volume>20</volume>
  <fpage>1998</fpage>
  <lpage>2003</lpage>
  <pub-id pub-id-type="doi">10.1038/mt.2012.146</pub-id>
  <?supplied-pmid 22871663?>
  <pub-id pub-id-type="pmid">22871663</pub-id>
 </element-citation>
</ref>
